News|Articles|November 20, 2026

Guselkumab in Axial Psoriatic Arthritis: Phase 4 STAR Trial Results

Author(s)Tim Smith
Listen
0:00 / 0:00

Key Takeaways

  • STAR randomized 411 patients with active PsA, centrally read MRI-confirmed axial inflammation, elevated CRP, and inadequate response to non-biologic therapies to guselkumab Q4W, Q8W, or placebo for 24 weeks.
  • Week-24 BASDAI improvements favored guselkumab (−3.3 Q4W; −2.9 Q8W) versus placebo (−2.1), supporting efficacy for axial symptom control in this enriched axial-PsA population.
SHOW MORE

Guselkumab improved axial symptoms and MRI-assessed sacroiliac joint inflammation vs placebo in axial psoriatic arthritis in the phase 4 STAR trial.

Frequently Asked Questions:

  • What is the STAR trial?
    STAR is a phase 4, randomized, double-blind, placebo-controlled trial of guselkumab in 411 biologic-naive adults with active psoriatic arthritis and axial involvement confirmed by MRI.
  • Did guselkumab reduce sacroiliac joint inflammation?
    Yes. SPARCC MRI scores fell by 7.1 points with dosing every 4 weeks and 5.2 points with dosing every 8 weeks, compared with 2.4 points with placebo, at week 24.
  • Is guselkumab approved for every-4-week dosing in psoriatic arthritis?
    No. The every-4-week regimen evaluated in STAR is not approved in the US.

Guselkumab (Tremfya) significantly improved axial symptoms and reduced MRI-detected sacroiliac joint inflammation versus placebo in biologic-naive adults with active psoriatic arthritis (PsA) and axial involvement. Johnson & Johnson shared the late-breaking phase 4 STAR results at the 2026 Emirates Society for Rheumatology Annual Meeting.¹

There has been little prospective evidence specific to axial psoriatic arthritis, in part because no validated classification criteria exist for this disease domain. Johnson & Johnson described STAR as the first randomized, double-blind, placebo-controlled trial designed to prospectively study an interleukin-23 (IL-23) inhibitor in patients with MRI-confirmed axial involvement.¹,²

What Did the STAR Trial Show for Guselkumab in Axial Psoriatic Athritis?

STAR (NCT04929210) enrolled 411 participants worldwide with active psoriatic arthritis, axial inflammation confirmed by centrally read MRI, and elevated C-reactive protein (CRP). All had active disease despite prior treatment with non-biologic disease-modifying antirheumatic drugs, apremilast, or nonsteroidal anti-inflammatory drugs.² Those assessed were randomized to guselkumab 100 mg every 4 weeks (Q4W), guselkumab every 8 weeks (Q8W), or placebo for 24 weeks. All participants then received open active therapy for another 24 weeks.¹

The trial was shown to have met its primary endpoint, change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at week 24. On the 0-to-10 scale, mean BASDAI scores fell by 3.3 points with Q4W dosing and 2.9 points with Q8W dosing, compared with 2.1 points with placebo.¹

Both regimens also beat placebo on the Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP), with reductions of 1.5 and 1.3 points, respectively, versus 0.8 points with placebo. Both active-arm improvements were found to have exceeded the 1.1-unit threshold commonly used to define a clinically important change.¹

How Did Guselkumab Affect MRI-Assessed Sacroiliac Joint Inflammation?

Investigators quantified sacroiliac joint inflammation on MRI using the Spondyloarthritis Research Consortium of Canada (SPARCC) score. Guselkumab lowered SPARCC scores by 7.1 points with Q4W dosing and 5.2 points with Q8W dosing, compared with 2.4 points with placebo. Both reductions were more than double the placebo response.¹

According to the company, guselkumab treatment also produced high rates of skin clearance in both dosing arms, in line with results from the DISCOVER-1, DISCOVER-2, and APEX trials. Improvement on the Health Assessment Questionnaire-Disability Index was numerically greater with Q8W dosing but did not reach statistical significance.¹

Safety findings matched the known profile of guselkumab across psoriatic disease, and no new safety concerns were identified.¹ In the US, guselkumab is approved for active psoriatic arthritis in adults and in children 6 years and older weighing at least 40 kg. The Q4W regimen tested in STAR is not an FDA-approved dosing schedule.¹

References

  1. Johnson & Johnson. Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness. Published November 20, 2026. Accessed November 20, 2026. https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-data-in-psoriatic-arthritis-PsA-shows-TREMFYA-guselkumab-is-the-only-advanced-therapy-to-demonstrate-MRI-confirmed-improvements-in-spinal-pain-and-stiffness/default.aspx
  2. Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23(1). doi:10.1186/s13063-022-06589-y

Related to this article